| 05.20.24 | Gilead's liver dise ase drug justifies $4.3B price w ith new data; Endeavor’s IPF dru g improves lung function in ph. 2

Laden...

6 maanden geleden

Html
Tekst

Transformative Advances in Cancer Immunotherapy: Progress and Promise

Among the most promising immunotherapy approaches are immune checkpoint blockade, adoptive cell therapies, therapeutic vaccines, oncolytic viruses, and mono, bi and trispecific antibodies. Download our white paper to explore advances in cancer immunotherapy and learn how Premier Research can maximize the potential of your program throughout the development lifecycle.

Today’s Big News

May 20, 2024

Gilead's new liver disease med continues to deliver the goods ahead of FDA verdict

Taking on pharma giants, Endeavor links IPF drug to improved lung function in phase 2

Third Rock, J&J neuroscience spinout Rapport is first biotech to outline summer IPO plans

Fierce Biotech Layoff Tracker 2024: Akari bids adieu to 67% of staff; Erasca erases 18% of roles


A message from Worldwide Clinical Trials

Featured

Gilead's new liver disease med continues to deliver the goods ahead of FDA verdict

By James Waldron

Three months after spending $4.3 billion on CymaBay Therapeutics for its primary biliary cholangitis med, Gilead Sciences has presented a fresh slice of data as a reminder of seladelpar’s potential while an FDA decision is pending.

Taking on pharma giants, Endeavor links IPF drug to improved lung function in phase 2

By Nick Paul Taylor

Endeavor BioMedicines has linked its Hedgehog inhibitor to improved lung function in a phase 2a idiopathic pulmonary fibrosis (IPF) study, sending a sonic pulse through a sector currently dominated by drugs that only slow the decline of the disease..

Third Rock, J&J neuroscience spinout Rapport is first biotech to outline summer IPO plans

By James Waldron

The new year burst of biotech IPOs may have sputtered out months ago, but Rapport Therapeutics is a reminder that companies are still willing to test the waters of the public markets.

Fierce Biotech Layoff Tracker 2024: Akari bids adieu to 67% of staff; Erasca erases 18% of roles

By Gabrielle Masson,Max Bayer

We really didn't want to have to create another Layoff Tracker this year. But here we are, launching the third annual iteration tracking biopharma layoffs.

One major hurdle in therapeutic development is the risk for unwanted immunogenicity, which can lead to decreased efficacy and safety. Gain insight into available tools and de-risk your pipeline - Join your colleagues to discuss on May 22

AstraZeneca places $1.5B bet on end-to-end ADC manufacturing in Singapore

By Fraiser Kansteiner

Riding high on its Daiichi Sankyo-partnered antibody drug conjugate (ADC) Enhertu—and banking on an approval for its next ADC contender datopotamab durextecan this winter—AstraZeneca is placing a big bet on the cancer-fighting technology as it blueprints a massive manufacturing investment in Asia.

Hims & Hers expands weight loss program to include access to GLP-1 medications

By Heather Landi

Six months after launching its weight loss program, online health and wellness company Hims & Hers added compounded GLP-1 medications to its offerings.

First Wave BioPharma comes ashore with new name as it prepares for phase 3 trial

By Andrea Park

The company formerly known as First Wave BioPharma has found itself on dry land with a decidedly non-aquatic new moniker.

R3 Vascular raises $87M to test its bioresorbable scaffold for blocked arteries below the knee

By Conor Hale

On the heels of a groundbreaking FDA approval for a major medtech, a Silicon Valley startup is shaping up to be a possible competitor.

Fierce podcasts

Don’t miss an episode

From cell collection to commercial contracting: Advancements in cell & gene therapy manufacturing (Part II)

This week’s episode of “The Top Line” is the second part of a three-part series exploring the latest advancements in cell and gene therapy manufacturing.

A deep dive into health system and health plan Q1 earnings

Fulfilling the promise of cell & gene therapies through manufacturing (Part I)


A message from Nikon

Resources

Whitepaper

Comprehensive Cell Solutions: Focus on Cellular Therapy Collections

Precision collection of cell therapy source material doesn’t happen by chance. Our new whitepaper illuminates the science and strategies for successful apheresis.

Sponsored by: Comprehensive Cell Solutions

Whitepaper

In Vitro Antibodies – Next-Gen Science Delivers Optimized Candidates

Learn how Specifica’s in vitro antibody discovery platform can deliver better antibodies than traditional immunization approaches.

Sponsored by: Specifica, a Q2 Solutions company

Whitepaper

Branded Digital Companions in Biopharma

This paper defines “digital companions” in biopharma, explores their value from the patient & company perspectives, & outlines a process for successfully fielding a new digital companion.

Presented by: Blue Matter, strategic consultants in the life sciences

eBook

Designing Patient-Centered Endpoint in Rare Disease Trials

To make every rare disease trial count, we design patient-centric, relevant strategies for sponsors and caregivers to produce impactful results every time.